How iX Biopharma turned conviction into opportunity

iX Biopharma, a Singapore-based pharmaceutical company, has turned a significant setback into a major opportunity, securing a US$41 million contract from the United States Department of Defense (DoD). This funding is earmarked for the development of its lead drug candidate, Wafermine, which the DoD identified as a potential solution for battlefield pain management.

The contract not only provides crucial financial backing but also paves the way for the potential early deployment of Wafermine on the battlefield via an emergency use authorization. This development underscores the company's persistence after losing a key licensing partner in late 2023, which saw the rights to Wafermine revert to iX Biopharma in 2024.

“

How do you know we won’t pull a rabbit out of the hat?

Despite the initial disappointment, the company's leadership, including Chairman and CEO Eddy Lee, encouraged the team to remain open to new possibilities. Chief Commercial Officer Eva Tan recalled Lee's message during a funding options briefing: "How do you know we won’t pull a rabbit out of the hat?" This spirit of innovation and belief in their product fueled their efforts to find new commercial pathways.

“

IT’S EASY TO GIVE UP WHEN THE MARKET DOESN’T RECOGNISE YOUR VALUE YET. WHAT HAS KEPT US MOVING FORWARD IS CLARITY ON THE PROBLEM WE’RE SOLVING.

Tan highlighted the significance of this milestone, stating, "We're not from one of the traditional global biotech centers such as Boston or San Diego, and we're not a large pharmaceutical company with unlimited capital. Yet our technology was assessed on its merits and selected for a mission-critical program. That’s what makes this milestone meaningful to us: What we built from Singapore has demonstrated its relevance on the global stage."

Founded in 2008 and built around its proprietary WaferiX drug-delivery platform, iX Biopharma reformulates existing drugs into wafers that dissolve under the tongue. This approach aims to reduce the time, cost, and risk associated with developing new treatments by improving drug delivery.

“

We’re not from one of the traditional global biotech centers such as Boston or San Diego, and we’re not a large pharmaceutical company with unlimited capital. Yet our technology was assessed on its merits and selected for a mission-critical program. That’s what makes this milestone meaningful to us: What we built from Singapore has demonstrated its relevance on the global stage.